FENNEC PHARMACEUTICALS INC. - Common Shares (FENC) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2017 to Q4 2025

Type / Class
Equity / Common Shares
Symbol
FENC on Nasdaq
Shares outstanding
27,691,200
Price per share
$7.70
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
13,863,242
Total reported value
$129,757,954
% of total 13F portfolios
0%
Share change
+261,332
Value change
+$2,614,051
Number of holders
83
Price from insider filings
$7.70
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of FENNEC PHARMACEUTICALS INC. - Common Shares (FENC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Solas Capital Management, LLC 8.2% +17% $11,277,104 +$1,640,189 2,250,919 +17% Solas Capital Management, LLC 31 Dec 2024
Rosalind Advisors, Inc. 7.5% $19,441,922 2,076,840 Rosalind Advisors, Inc. 30 Sep 2025
DG Capital Management, LLC 4.1% $5,584,607 1,114,692 DG Capital Management, LLC 31 Dec 2024

As of 30 Sep 2025, 83 institutional investors reported holding 13,863,242 shares of FENNEC PHARMACEUTICALS INC. - Common Shares (FENC). This represents 50% of the company’s total 27,691,200 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of FENNEC PHARMACEUTICALS INC. - Common Shares (FENC) together control 49% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Southpoint Capital Advisors LP 15% 4,077,214 0% 1% $38,162,723
Solas Capital Management, LLC 7.9% 2,187,902 -2% 12% $20,478,763
Rosalind Advisors, Inc. 7.5% 2,076,840 +1.5% 7.1% $19,439,222
BlackRock, Inc. 4.4% 1,211,806 -1.2% 0% $11,342,505
VANGUARD GROUP INC 3.5% 955,764 -1.2% 0% $8,945,951
AIGH Capital Management LLC 2.5% 681,501 +51% 2.2% $6,378,850
STATE STREET CORP 1.2% 341,201 +1.4% 0% $3,193,641
TANG CAPITAL MANAGEMENT LLC 1.2% 334,593 +1530% 0.12% $3,131,790
GEODE CAPITAL MANAGEMENT, LLC 1.1% 300,772 -1.3% 0% $2,815,225
MORGAN STANLEY 0.84% 232,402 -8.6% 0% $2,175,283
HARBERT FUND ADVISORS, INC. 0.64% 177,815 -38% 11% $1,664,348
GENDELL JEFFREY L 0.5% 139,559 -0.11% 0.02% $1,306,272
NORTHERN TRUST CORP 0.47% 130,553 -0.7% 0% $1,221,976
Lion Point Capital, LP 0.44% 123,000 -37% 6.5% $1,151,280
CITADEL ADVISORS LLC 0.39% 107,496 +130% 0% $1,006,163
JANE STREET GROUP, LLC 0.26% 72,631 +45% 0% $679,826
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.21% 57,249 -6.6% 0% $535,851
Bank of New York Mellon Corp 0.19% 52,278 +0.9% 0% $489,325
Hartford Financial Management Inc. 0.18% 50,646 0% 0.13% $474,047
RHUMBLINE ADVISERS 0.12% 33,522 -1.1% 0% $313,757
BARCLAYS PLC 0.12% 33,038 -17% 0% $309,236
STATE OF WISCONSIN INVESTMENT BOARD 0.12% 32,100 +38% 0% $300,456
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.11% 30,700 +27% 0.01% $287,352
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 0.1% 27,055 0% 0% $253,235
GOLDMAN SACHS GROUP INC 0.1% 26,490 +66% 0% $247,946

Institutional Holders of FENNEC PHARMACEUTICALS INC. - Common Shares (FENC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 471 $3,627 +$8 $7.70 3
2025 Q3 13,863,242 $129,757,954 +$2,614,051 $9.36 83
2025 Q2 13,599,927 $112,877,891 +$2,365,576 $8.30 77
2025 Q1 13,390,166 $81,552,580 -$1,522,796 $6.09 68
2024 Q4 16,048,764 $101,424,709 +$7,283,101 $6.32 64
2024 Q3 14,931,283 $74,650,401 +$2,539,945 $5.00 62
2024 Q2 14,360,522 $87,743,157 -$6,402,228 $6.11 62
2024 Q1 14,487,904 $161,105,469 -$5,972,346 $11.12 64
2023 Q4 14,100 $158,202 +$158,202 $11.22 1
2023 Q3 14,245,636 $106,987,001 +$1,437,174 $7.51 53
2023 Q2 14,021,525 $123,812,964 +$9,262,191 $8.83 53
2023 Q1 13,040,023 $108,481,973 +$4,616,032 $8.32 53
2022 Q4 12,451,231 $119,532,387 +$10,696,886 $9.60 42
2022 Q3 11,367,575 $92,077,143 +$2,924,614 $8.10 29
2022 Q2 112 $1,000 -$14,000 $4.71 1
2022 Q1 11,437,604 $64,049,354 +$540,897 $5.60 24
2021 Q4 11,335,153 $49,873,524 -$2,267,671 $4.40 25
2021 Q3 11,649,016 $109,719,412 -$3,018,412 $9.42 30
2021 Q2 12,034,752 $87,728,799 -$14,239,355 $7.29 36
2021 Q1 14,332,788 $89,005,363 -$486,768 $6.21 48
2020 Q4 14,462,317 $107,736,409 +$5,055,901 $7.45 48
2020 Q3 13,830,213 $83,807,136 -$965,453 $6.06 50
2020 Q2 13,850,911 $115,652,682 +$37,785,610 $8.35 52
2020 Q1 9,462,229 $56,207,308 +$983,454 $5.94 25
2019 Q4 9,292,336 $60,284,402 -$39,068 $6.48 25
2019 Q3 8,465,848 $40,718,811 -$1,957,639 $4.81 21
2019 Q2 8,988,085 $35,952,664 -$3,102,283 $4.00 25
2019 Q1 9,583,050 $46,478,901 -$672,176 $4.85 41
2018 Q4 9,704,249 $61,912,244 +$1,841,986 $6.38 40
2018 Q3 9,432,851 $77,354,034 -$274,816 $8.20 41
2018 Q2 9,392,798 $98,080,863 +$18,177,550 $10.44 42
2018 Q1 7,623,490 $92,186,000 +$5,662,632 $12.09 20
2017 Q4 6,947,981 $69,573,000 +$17,996,926 $9.97 13
2017 Q3 5,214,607 $57,723,000 +$57,723,140 $11.08 9